This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The primary outcome measure for the study is change in six-minute walk distance from Baseline to Week 12. Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure.
mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with PreservedEjectionFraction (HFpEF).
In patients with heart failure with preservedejectionfraction (HFpEF), abnormal global longitudinal strain (GLS) is a strong predictor for clinical events and can help identity patients who are at risk for future decline in left ventricular ejectionfraction (LVEF). After a median follow-up of 4.6 years,
As heart failure with preservedejectionfraction (HFpEF) comprises half of all heart failure cases, understanding its management and effect on outcomes is crucial. Multivariate logistic and linear regression analyses were performed, adjusting for multiple patient and hospital confounders.
ABSTRACT Aims Heart failure outcomes remain poor despite advances in therapy. The European Society of Cardiology Heart Failure III Registry (ESC HF III Registry) aims to characterize HF clinical features and outcomes and to assess implementation of guideline-recommended therapy in Europe and other ESC affiliated countries.
Contemporary classification of HF categorizes it into HF with reduced ejectionfraction (HFrEF), HF with mildly reduced ejectionfraction (HFmrEF), and HF with preservedejectionfraction (HFpEF). Aggregate data comparing the risk profile of AF between these three HF categories are lacking.
Atrial fibrillation (AF) with comorbid heart failure with preservedejectionfraction (HFpEF) presents a significant management challenge. While the association between AF and heart failure with reduced ejectionfraction is extensively studied, the correlation between AF and HFpEF remains less explored.
Previous studies have demonstrated significant morbidity and mortality in patients with heart failure (HF) with reduced ejectionfraction (HFrEF), particularly with accompanying atrial fibrillation (AF).
Adjusted odds ratios (aOR) were calculated for outcomes and Kaplan-Meier survival analysis curves with log-rank tests over five-year follow-up were analyzed using R software.Results:There were 11384 participants matched to each cohort; the average age at diagnosis was 72.5 + 11.6 Patients with rheumatic valve disease were excluded.
BackgroundSystemic chronic inflammation plays a role in the pathophysiology of both heart failure with preservedejectionfraction (HFpEF) and metabolic dysfunction‐associated fatty liver disease. The study outcome was time to the first hospitalization for HF. In 10 019 middle‐aged individuals (mean age, 63.3±10.6
Meta-analysis on the main outcomes of angiotensin receptorneprilysin inhibitor (ARNI) in heart failure (HF) patients with end-stage kidney disease (ESKD) on dialysis. This effect was more pronounced in patients with HF with reduced ejectionfraction ( p interaction <0.0001).
The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preservedejectionfraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status. The primary outcome was the composite of cardiovascular death and total worsening HF events.
live with HF, 2 a complex clinical syndrome with symptoms and signs that result from any structural or functional impairment of ventricular filling or ejection of blood. Finerenone in Heart Failure with Mildly Reduced or PreservedEjectionFraction. 4 Approximately 6.7 million adults in the U.S. Bozkurt A, et al.
The main outcome was the composite of allcause mortality and first HF hospitalization. The mean age, body mass index, left ventricular ejectionfraction, and EAT volume were 57.0 During a median followup of 34 months, 169 patients (24.4%) died or were hospitalized for HF. Of 692 participants, 41.3% were women.
However, the relationship between PWR and adverse outcomes in patients with acute decompensated heart failure (ADHF) remains unclear. The primary outcome measure was all-cause mortality within 30 days of hospitalization. The primary outcome measure was all-cause mortality within 30 days of hospitalization.
ABSTRACT Aim Chronic obstructive pulmonary disease (COPD) is common in heart failure with a mildly reduced or preservedejectionfraction (HFmrEF/HFpEF) and is associated with worse outcomes. The primary outcome was a composite of cardiovascular death or worsening heart failure. 0.93]; COPD: HR 0.82 [95% CI 0.62–1.10];
Beta-blocker use and outcomes in patients with HFmrEF/HFpEF. Beta-blockers are commonly used in patients with heart failure and mildly reduced or preservedejectionfraction (HFmrEF/HFpEF). Outcomes were generally consistent across the patient subgroups examined.
ABSTRACT Background Left atrial (LA) myopathy is increasingly recognized as an important phenotypic trait in heart failure (HF) with preservedejectionfraction (HFpEF). Individuals with biatrial myopathy had an 84% higher risk of HF hospitalization or death as compared to those with isolated LA myopathy (HR 1.84; 95% CI, 1.16–2.92,
A summary of effect of sacubitril/valsartan in heart failure with preservedejectionfraction across the age spectrum. Aims To evaluate clinical outcomes, echocardiographic features, and the efficacy and safety of sacubitril/valsartan compared to valsartan across age groups in the PARAGON-HF trial.
Abstract Introduction Catheter ablation for atrial fibrillation (AF) reduces heart failure (HF) hospitalization in patients with HF with preservedejectionfraction (HFpEF). However, the long-term outcomes and subclinical HF after nonparoxysmal AF ablation in HFpEF patients have not been fully evaluated.
Global longitudinal strain (GLS) and clinical outcomes in heart failure with preservedejectionfraction (HFpEF). Almost 47% of patients with HFpEF had evidence of left ventricular (LV) subclinical dysfunction, defined as absolute LV GLS 0.1).
Compared with those who spent most of their time in a single room, people with heart failure with preservedejectionfraction (HFpEF) who were able to travel outside of their home without assistance were significantly less likely to be hospitalized or die within a year, according to a new study.
Abstract Aims Atrial fibrillation (AF) is common in heart failure (HF) and negatively impacts outcomes. The role of ablation-based rhythm control in patients with AF and HF with preserved (HFpEF) or mildly reduced ejectionfraction (HFmrEF) is not known. Usual care can include rhythm control in symptomatic patients.
Abstract Aims Patients with heart failure (HF) and mildly reduced ejectionfraction (HFmrEF) and preservedejectionfraction (HFpEF) are often treated with calcium channel blockers (CCBs), although the safety of CCBs in these patients is uncertain. The association between CCB use and outcomes was assessed.
The study, which is testing a novel rehabilitation program designed for older patients hospitalized with acute heart failure, is funded by a five-year, $30 million grant , awarded to Wake Forest University School of Medicine in 2022 by the National Institute of Aging, part of the National Institutes of Health.
Lilly’s blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preservedejectionfraction and obesity. vs. +15 KCCQ-CSS points). vs. -2.2%).
The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejectionfraction (HFrEF) and heart failure with preservedejectionfraction (HFpEF).
A secondary hierarchical outcome consisted of cardiovascular death, HF hospitalizations, urgent HF visits, and NTproBNP change. The win ratio for the hierarchical outcome was 1.09 (95% CI, 0.821.45;P=0.57) Safety end points were symptomatic hypotension, hyperkalemia, and worsening renal function. P=0.12) for outofhospital.
Impact of COVID-19 in patients with HF and mildly reduced and preservedejectionfraction. This study aimed to evaluate the association between COVID-19 and clinical outcomes among DELIVER participants. This study aimed to evaluate the association between COVID-19 and clinical outcomes among DELIVER participants.
Compared with those who spent most of their time in a single room, people with heart failure with preservedejectionfraction (HFpEF) who were able to travel outside of their home without assistance were significantly less likely to be hospitalized or die within a year, according to a study being presented at the American College of Cardiology's Annual (..)
Background:Left ventricular global longitudinal strain (GLS) has been associated with mortality and heart failure hospitalization (HFH) among subjects with chronic heart failure, but not in patients with acute decompensated heart failure (ADHF).
Abstract Aims It is common in heart failure (HF) trials, especially in HF with preserved (HFpEF) and mildly reduced ejectionfraction (HFmrEF), to select for increased risk of outcomes (enrichment). We investigated the association between loop diuretic use and common trial outcomes. Among 25986 patients, 41.3%
Increasing trait multiplicity within a given patient was associated with worse exercise hemodynamics, poorer exercise capacity, lower cardiac output reserve, and greater risk for HF hospitalization or death (HR 1.74, 95% CI:1.08-2.79 for 0-1 vs ≥2 phenogroup traits present). This article is protected by copyright. All rights reserved.
The H2FPEF score and probability were developed to assist in heart failure with preservedejectionfraction (HFpEF) diagnosis. Survival analysis was performed (Outcome: PAH related-hospitalization or death). Significant predictors of outcomes were identified using Cox logistic regression analysis.
Cox regression models were used to assess the association between cardiometabolic comorbidity burden and time to allcause and HF hospitalization at 1 year, adjusting for age, sex, race or ethnicity, and insurance status, smoking, prior hospitalization, and Elixhauser comorbidity index.
The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejectionfraction (HFrEF) and heart failure with preservedejectionfraction (HFpEF).
Early changes in estimated glomerular filtration rate (eGFR) post-initiation of empagliflozin in patients with heart failure with preservedejectionfraction (HFpEF). CI, confidence interval; CV, cardiovascular; HHF, hospitalization for heart failure; HR, hazard ratio; LVEF, left ventricular ejectionfraction.
Michael’s Hospital , University of Toronto) at the American Diabetes Association’s 2024 Scientific Sessions and published in the Journal of the American College of Cardiology ( JACC ). mg administered to participants once weekly vs placebo on the STEP-HFpEF program’s dual primary and confirmatory secondary, and exploratory outcomes by sex.
BackgroundLeft ventricular dysfunction is characterized by systolic and diastolic parameters, leading to heart failure (HF) with reduced or preservedejectionfraction (EF), respectively. Patients were followed to the end points of all‐cause death and cardiovascular, HF, or cardiac arrest hospitalizations.
Background:SGLT2 inhibitors have demonstrated efficacy in reducing cardiovascular death and hospitalization and are recommended as first-line therapy for hear failure (HF) in adults due to acquired heart diseases. We excluded articles related to acute decompensated HF and HF with preservedejectionfraction.
Background Heart failure (HF) is associated with high levels of resource use and mortality, but prior UK studies have not compared outcomes by HF subtype (HF with reduced ejectionfraction (HFrEF) and HF with preservedejectionfraction (HFpEF)) in large patient populations.
CA-125 was only prognostic in those with reduced ejectionfraction and not associated with congestive symptoms or signs. CI, confidence interval; CV, cardiovascular; HF, heart failure; HFpEF, heart failure with preservedejectionfraction; HFrEF, heart failure with reduced ejectionfraction; HHF, hospitalization for heart failure.
Sodium–glucose cotransporter 2 (SGLT2) inhibitors improve outcomes in heart failure, which has been experimentally linked to AMPK. Methods and results Growth differentiation factor-15 was determined in serum samples from the EMPEROR-Reduced and EMPEROR-Preserved trials. 1.71; p < 0.001).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
105 
Let's personalize your content